Contributors. Preface. nI: Introductory Chapter. Cardiomyopathies and Heart Failure: Biomolecular, Infections and Immune Mechanisms; A. Matsumori. nII: Cytokines in Cardiomyopathies and Heart Failure. 1. Chemokines and Cardiovascular Diseases; K. Matsushima, et al. 2. Negative Regulator of Cytokine Signaling (SOCS) Genes in Inflammation; I. Kinjyo, et al. 3. The Interleukin-6 Family of Cytokines and their Receptors in Patients with Congestive Heart Failure; K. Yamauchi-Takihara, et al. 4. Animal Model of Cardiomyopathy Due to Overexpression of TNF-alpha; T. Kubota. nIII: Autoimmunity in Cardiomyopathies and Heart Failure. 5. Myosin Autoreactive T Cells and Autoimmune Myocarditis: Lessons from the Disease Caused by Cardiac Myosin Peptide CM2; T. Izumi, et al. 6. Autoimmunity in Cardiomyopathies; M. Noutsias, et al. 7. Anti-G-Protein Coupled Cardiac Receptor Autoantibodies in Dilated Cardiomyopathy; M. Fu. 8. Clinical Significance of Circulating Cardiac Autoantibodies in Dilated Cardiomyopathy and Myocarditis; A.L.P. Caforio, W.J. McKenna. nIV: Mast Cell Mediators and Human Diseases: Basic Aspects. 9. Development of Mast Cells: Process and Regulatory Mechanisms; Y. Kitamura, et al. 10. Mast Cells in Experimental Myocardial Infarction; N.G. Frangogiannis, M.L. Entman. 11. possible Involvement of Mast Cells in the Development of Fibrosis; M. Kurosawa, et al. 12. Human Mast Cell Chymase and 31 Amino Acid Endothelin-1; H. Kido, et al. 13. Tryptase from Human mast Cells; L.B. Schwartz. 14. Effects of the Tryptase Receptor Activating Peptide and Antibodies against the Tryptase Receptor PAR-2 on Neonatal Rat Cardiomyocytes in Culture; G. Wallukat, et al. nV: Mast Cell Mediators and Human Diseases Clinical Aspects. 15. Role of Human Heart Mast Cells in Immunologic and Inflammatory Mechanisms Underlying Cardiovascular Disorders; G. Marone, et al. 16. Mast Cells in Atherosclerotic Human Coronary Arteries: Implications for Coronary Fatty Streak Formation and Plaque Erosion or Rupture; P.T. Kovanen, et al. 17. The Key Role of Mast Cells in the Evolution to Congestive Heart Failure; M. Hara, et al. nVI: Viral Etiology of Cardiomyopathies and Heart Failure. 18. Links between Viral Infections and Heart Disease; C.J. Gauntt, et al. 19. Molecular Detection and Characterization of Human Enteroviruses; M.A. Pallansch, M.S. Oberste. 20. Detection and Biological Implications of Genetic Memeory in Viral Quasispecies; E. Domingo, et al. 21. The Group B Coxsackieviruses as Vaccines and Vectors; N.M. Chapman, et al. 22. Detection of Important Diagnostic Markers of HCV Infection; H.A. Fields. nVII: Diagnosis and Treatment of Myocarditis. 23. Large Animal Model of Viral Myocarditis; M.K. Njenga, et al. 24. Hepatitis C Virus and Cardiomyopathy; Y. Sato, et al. 25. Diagnosis and Treatment of Myocarditis: The Role of Adenovirus Infection in Cardiomyopathy and Heart Failure; J.A. Towbin, N.E. Bowles. 26. The Natural History of Viral Myocarditis: Pathogenic Role of Adrenergic System Dysfunction in the Development of Idiopathic Dilated Cardiomyopathy; P.M. S
DUCTORYCHAPTER CARDIOMYOPATHIESANDHEARTFAILURE Biomolecular,InfectiousandImmuneMechanisms AkiraMatsumori,MD,PhD DepartmentofCardiovascularMedicine KyotoUniversityGraduateSchoolofMedicine Kyoto,Japan 1 SUMMARY Theclinicalpresentationofviralmyocarditisisvariable. Whenmyocardial necrosis is diffuse, congestive heart failure develops, and later, dilated cardiomyopathy. If the myocardial lesions are localized, a ventricular aneurysmforms. Whencomplicatedbyarrhythmias,myocarditispresentsas arrhythmogenic right ventricular cardiomyopathy. When myocardial necrosisislocalizedtothesubendocardialregion,restrictivecardiomyopathy may develop. While it has not been established that hypertrophic cardiomyopathy maybeacomplicationofviral myocarditis, asymmetrical septal hypertrophy has, in fact, sometimesbeen observed in patients with myocarditis. TheimportanceofhepatitisCvirusinfectionhasrecentlybeen notedinpatientswithmyocarditis,dilatedandhypertrophiccardiomyopathy.
Springer Book Archives